Skin News

Monday, December 08, 2008 Say Goodbye to Plantar Fasciitis After 15-Minute Treatment
Combining an ultrasound-guided dry needling technique with steroid injection is 95% effective at relieving plantar fasciitis within 3 weeks...

Friday, December 05, 2008 SSc Risk 60-Fold Higher in Raynaud's with SSc Antibodies, NCM Changes
Microvascular damage and systemic sclerosis (SSc)-specific antibodies can predict which Raynaud's phenomenon patients will progress to systemic sclerosis, and when...

Monday, November 24, 2008 Scleroderma Stem Cell Transplants Advance, Phase III Studies Recruiting Patients
Pilot data on systemic sclerosis (SSc) patients treated with autologous stem cell transplants suggest durable improvements in skin thickening and lung function. Phase III randomized trials are still open to enrollment...

Tuesday, November 18, 2008 Centocor's Golimumab Gives Durable Skin, Joint Relief in Psoriatic Arthritis, ACR Studies Say
More than half of active psoriatic arthritis patients receiving subcutaneous injections of 50 mg or 100 mg of golimumab (CNTO 148) every 4 weeks showed improvements that lasted through 1 year in the joint and skin symptoms...

Monday, October 20, 2008 Gleevec/CYC Combo Emerging as Novel Approach for Scleroderma Lung Disease
Adding the oncology drug imatinib (Gleevec^®) to cyclophosphamide offers a 2-pronged strategy that might be effective in scleroderma-associated pulmonary complications...

Wednesday, October 15, 2008 Genentech Issues Dear Healthcare Provider Letter Regarding Case of PML in a Psoriasis Patient Under Long-Term Treatment With Raptiva^®
The 70-year old patient had received Raptiva^® (efalizumab) for >4 years to treat chronic plaque psoriasis before being diagnosed with progressive multifocal leukoencephalopathy...

Wednesday, October 08, 2008 Incyte's Topical JAK Inhibitor Shows Positive Proof-of-Concept Results in Two Phase IIa Clinical Trials in Patients with Mild-to-Moderate Psoriasis; Phase IIb Expected to Start October 2008
Results from the first study demonstrated that INCB18424 was well tolerated at all doses and significantly improved overall total lesion score (erythema + scaling + thickness)...

Monday, September 29, 2008 Abbott Reports Continuous Treatment With Humira^® Achieves Superior Long-Term Efficacy for Psoriasis Patients in the US and Europe Versus Interrupting Treatment
The findings were from the company's pivotal 52-week REVEAL study and the period of open-label treatment that followed...

Thursday, September 25, 2008 Centocor’s Ustekinumab Demonstrates Superior Efficacy to Enbrel^® (Etanercept) in Treatment of Moderate-to-Severe Plaque Psoriasis
Greater proportion of patients receiving ustekinumab achieved significant skin clearance versus patients receiving Enbrel...

Friday, September 12, 2008 BioCryst Reports Results From Phase IIa Trial of PNP Inhibitor in Psoriasis; No Evidence of Clinical Efficacy
BCX-4208 is a potent, rationally-designed, inhibitor of PNP—a purine salvage pathway enzyme that is essential for the proliferation of activated T-cells...